XML 44 R28.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information (Tables)
 3 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Revenue
The following table presents revenue for the two reportable segments and disaggregated revenue within the remaining operating segments, included in Other, and Corporate:
Three Months Ended September 30,
(in millions)20252024
Pharmaceutical and Specialty Solutions$59,205 $47,990 
Global Medical Products and Distribution3,184 3,123 
Nuclear and Precision Health Solutions436 373 
at-Home Solutions1,115 739 
OptiFreight® Logistics
90 74 
Other1,641 1,186 
Total segment revenue
64,030 52,299 
Corporate (1)(21)(22)
Total revenue$64,009 $52,277 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Revenue from External Customers by Geographic Areas [Table Text Block]
The following table presents revenue by geographic area:
Three Months Ended September 30,
(in millions)20252024
United States$63,611 $51,891 
International419 408 
Total segment revenue
64,030 52,299 
Corporate (1)(21)(22)
Total revenue$64,009 $52,277 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment
The following table presents segment profit for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
Three Months Ended September 30, 2025
(in millions)PharmaGMPDOtherTotal
Segment revenue
$59,205 $3,184 $1,641 $64,030 
Cost of product sold
57,857 2,633 1,221 61,711 
SG&A681 505 254 1,440 
Total segment expenses
58,538 3,138 1,475 63,151 
Segment profit
$667 $46 $166 $879 
Corporate (1)
(211)
Consolidated operating
earnings
$668 
Three Months Ended September 30, 2024
(in millions)PharmaGMPDOtherTotal
Segment revenue
$47,990 $3,123 $1,186 $52,299 
Cost of product sold
46,909 2,604 884 50,397 
SG&A551 511 198 1,260 
Total segment expenses
47,460 3,115 1,082 51,657 
Segment profit
$530 $8 $104 $642 
Corporate (1)
(74)
Consolidated operating
earnings
$568 
(1)     Corporate revenue and expenses consists of the elimination of inter-segment revenue and other revenue and expenses not allocated to the segments.
Assets by Reportable Segment
The following table presents total assets for two reportable segments and the remaining operating segments, included in Other, and Corporate:
(in millions)September 30, 2025June 30, 2025
Pharmaceutical and Specialty Solutions$38,683 $37,313 
Global Medical Products and Distribution7,133 6,889 
Other4,049 4,045 
Corporate
5,363 4,875 
Total assets$55,228 $53,122 
Segment, Reconciliation of Other Items from Segments to Consolidated
The following tables present depreciation and amortization and additions to property and equipment for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
Three Months Ended September 30,
(in millions)20252024
Pharmaceutical and Specialty Solutions$61 $27 
Global Medical Products and Distribution55 49 
Other29 18 
Corporate
88 88 
Total depreciation and amortization$233 $182 
Three Months Ended September 30,
(in millions)20252024
Pharmaceutical and Specialty Solutions$32 $11 
Global Medical Products and Distribution19 23 
Other15 12 
Corporate
42 44 
Total additions to property and equipment
$108 $90 
Long-Lived Assets by Geographic Areas
The following table presents property and equipment, net by geographic area:
(in millions)September 30, 2025June 30, 2025
United States
$2,396 $2,422 
International
435 436 
Total property and equipment, net$2,831 $2,858